Comparing the current results to its competitors, Arrivent Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.84 %, recorded in the same quarter.
Arrivent Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, focusing on the development of treatments for non-small cell lung cancer (NSCLC). It faces competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and both public and private research organizations. Many smaller biotechnology firms collaborate with larger companies to support research, development, commercialization, or to develop more effective treatments. The company expects competition to increase as new therapies, technologies, and data emerge in oncology and NSCLC treatment. Competitors targeting EGFR mutation-positive NSCLC include AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Inc., Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim, and Bayer AG.
September 9, 2024
Title : Promising Phase 1b Data Elevates ArriVent s Firmonertinib as a Leading Candidate for EGFR PACC Mutant NSCLCAt the 2024 World Conference on Lung Cancer, ArriVent BioPharma presented compelling interim data from their global Phase 1b trial, showcasing the efficacy of Firmonertinib a selective EGFR inhibitor designed for patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). This announcement has sent ripples through the oncology community, revealing significant implications for both patients and the biopharmaceutical landscape.The trial s results demonstrated an impressive 81.8% overall response rate (ORR) as evaluated by blinded independent central review (BICR) at the pivotal 240 mg dose....
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
Sources:
Arrivent Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arrivent Biopharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
